CurrentEndo
Get Weekly

CurrentEndo coverage · page 43 of 55

Diabetes, Obesity and Metabolism

Briefs 1,681–1,720 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Improved glycaemic control induced by evening activity breaks does not persist overnight amongst healthy adults: A randomized crossover trial

    Randomized controlled trial

  2. Diabetes Obes Metab

    Healthy Outcomes through Peer Educators: Feasibility of a peer support diabetes prevention programme for African‐American grandmother caregivers

    Randomized controlled trialT2D & other

  3. Diabetes Obes Metab

    Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis

    Meta-analysisT2D & other

  4. Diabetes Obes Metab

    Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study

    Randomized controlled trialT2D & other

  5. Diabetes Obes Metab

    Evaluating the global impact of low physical activity on type 2 diabetes: Insights from the global burden of disease 2019 study

    Secondary analysisT2D & other

  6. Diabetes Obes Metab

    Short, frequent, light‐intensity walking activity improves postprandial vascular‐inflammatory biomarkers in people with type 1 diabetes: The SIT‐LESS randomized controlled trial

    Randomized controlled trialT1D

  7. Diabetes Obes Metab

    Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide ‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database

    Meta-analysisT2D & other

  8. Diabetes Obes Metab

    Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial

    Randomized controlled trialT1D

  9. Diabetes Obes Metab

    Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study

    Cohort studyComplications

  10. Diabetes Obes Metab

    Patterns of initial and first‐intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010–2020: A retrospective population‐based cohort study

    Cohort studyT2D & other

  11. Diabetes Obes Metab

    Dual glucagon‐like peptide ‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity

    Randomized controlled trialObesity

  12. Diabetes Obes Metab

    TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes

    Randomized controlled trialT2D & other

  13. Diabetes Obes Metab

    The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis

    Meta-analysisT2D & other

  14. Diabetes Obes Metab

    Intra‐pancreatic fat is associated with continuous glucose monitoring metrics

    Cross-sectional studyTechnology

  15. Diabetes Obes Metab

    Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes

    Secondary analysis

  16. Diabetes Obes Metab

    Comparison of estimated glomerular filtration rate change with sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide ‐1 receptor agonists among people with diabetes: A propensity‐score matching study

    Cohort studyT2D & other

  17. Diabetes Obes Metab

    During an 18‐month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range

    Randomized controlled trialTechnology

  18. Diabetes Obes Metab

    Could poor glycaemic control be a predictor of walking speed decline in older adults? Evidence from the English Longitudinal Study of Ageing

    Cohort studyT2D & other

  19. Diabetes Obes Metab

    Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression

    Meta-analysisT2D & other

  20. Diabetes Obes Metab

    The effect of bolus advisors on glycaemic parameters in adults with diabetes on intensive insulin therapy: A systematic review with meta‐analysis

    Meta-analysisTechnology

  21. Diabetes Obes Metab

    The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis

    Cross-sectional studyObesity

  22. Diabetes Obes Metab

    Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial

    Randomized controlled trialComplications

  23. Diabetes Obes Metab

    Analyses of potential causal contributors to increased waist/hip ratio‐associated cardiometabolic disease: A combined and sex‐stratified Mendelian randomization study

    Research articleT2D & other

  24. Diabetes Obes Metab

    Efficacy of 1‐hour postload plasma glucose as a suitable measurement in predicting type 2 diabetes and diabetes‐related complications: A post hoc analysis of the 30‐year follow‐up of the Da Qing IGT and Diabetes Study

    Secondary analysisT2D & other

  25. Diabetes Obes Metab

    Effects of home‐based exergaming on cardio‐metabolic and cognitive health in physically inactive individuals

    Research article

  26. Diabetes Obes Metab

    Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts

    Cohort studyT2D & other

  27. Diabetes Obes Metab

    Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis

    Meta-analysisObesity

  28. Diabetes Obes Metab

    The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes

    Cohort studyObesity

  29. Diabetes Obes Metab

    Hydrogel dressings for diabetic foot ulcer: A systematic review and meta‐analysis

    Meta-analysisComplications

  30. Diabetes Obes Metab

    Low‐grade inflammation in persons with recently diagnosed type 2 diabetes: The role of abdominal adiposity and putative mediators

    Cross-sectional studyT2D & other

  31. Diabetes Obes Metab

    The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials

    Meta-analysisObesity

  32. Diabetes Obes Metab

    Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study ( PIONEER REAL Canada)

    Cohort studyT2D & other

  33. Diabetes Obes Metab

    Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model

    Diagnostic or prognostic studyT1D

  34. Diabetes Obes Metab

    A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study

    Randomized controlled trialT2D & other

  35. Diabetes Obes Metab

    Ingesting probiotic yogurt containing Lactiplantibacillus plantarum OLL2712 improves glycaemic control in adults with prediabetes in a randomized, double‐blind, placebo‐controlled trial

    Randomized controlled trialT2D & other

  36. Diabetes Obes Metab

    Sex‐specific associations between haemoglobin glycation index and the risk of cardiovascular and all‐cause mortality in individuals with pre‐diabetes and diabetes: A large prospective cohort study

    Cohort studyT2D & other

  37. Diabetes Obes Metab

    Associations of diabesity with all‐cause and cardiovascular disease mortality: Findings from the Mexico City Prospective Study

    Cohort studyObesity

  38. Diabetes Obes Metab

    Retinal vascular density as a potential biomarker of diabetic cerebral small vessel disease

    Cross-sectional studyComplications

  39. Diabetes Obes Metab

    Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase

    Randomized controlled trialReproductive endocrine

  40. Diabetes Obes Metab

    Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta‐regression analysis of 120 randomized controlled trials

    Randomized controlled trialT2D & other

All 2,200 Briefs in ExploreShowing Briefs 1,681–1,720 of 2,200, newest first